Orphan Drugs Market Scope And Analysis

  • Report Code : TIPRE00005799
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Orphan Drugs Market Scope and Key Players - 2031

Buy Now

Orphan Drugs Market Report Orphan Drugs Market Size and Share Orphan Drugs Market Scope and Analysis

Orphan Drugs Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Active ingredients
  • Obinutuzumab
  • Lenalidomide
  • Brentuximab
  • Vedotin
  • Riociguat
  • Ofatumumab
  • Nelarabine
  • Bosutinib
  • Mannitol
  • Carglumic acid
  • Aztreonam
  • Histamine hydrochloride
  • Eliglustat
  • Cabozantinib
  • Ramucirumab
  • Decitabine
  • Defibrotide
By Disease
  • Hodgkin lymphoma
  • Paroxysmal nocturnal hemoglobinuria
  • Chronic thromboembolic pulmonary hypertension
  • Chronic lymphocytic leukemia
  • Chronic Myeloid Leukaemia
  • T-cell acute lymphoblastic leukemia
  • Philadelphia chromosome positive chronic myelogenous leukaemia
  • Cystic fibrosis
  • acute myeloid leukaemia
  • Multiple Myeloma
  • Isovaleric acidaemia
  • Gaucher disease type 1
  • Metastatic medullary thyroid carcinoma
  • Advanced gastric cancer or gastro-esophageal jun
By End User
  • Hospitals
  • Ambulatory Surgical Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • F Hoffmann La Roche Ltd
  • Eli Lilly and Company
  • Alexion
  • CELGENE CORPORATION
  • Novartis AG
  • Takeda Pharmaceuticals Company Limited
  • Biogen
  • Bristol Myers Squibb Company
  • Bayer AG